On May 26, 2021 Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, reported a new collaboration with a Yale School of Medicine research team focused on identifying antigens expressed in patients with late-stage, advanced metastatic melanoma, and determining which of these antigens activate T cells in the tumor (Press release, Repertoire, MAY 26, 2021, View Source [SID1234580636]). The collaboration will seek to understand the specificity of various subsets of T cells with the goal of uncovering new antigens and their T cells, with potential for future incorporation into Repertoire’s cell therapy and other development programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study will discover new immunodominant epitopes and determine the specificity of T cells obtained from patients with metastatic melanoma. The university research team will provide human T cell receptor (TCR) sequences to Repertoire, which will use its proprietary DECODE platform to determine the novel antigens that these TCRs identify. The team’s deep understanding of translational science in oncology, coupled with Repertoire’s platform technology, may generate unique insights leading to the development of novel immune medicines.
The research team will be led by David A. Hafler, MD, FANA, William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, Yale School of Medicine; Chair, Department of Neurology and Neurologist-in-Chief, Yale New Haven Hospital.
"We’re pleased to initiate this collaboration with Dr. Hafler and his team at Yale University, particularly given their deep expertise in pioneering translational science in difficult disease areas, including advanced melanoma," said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. "Our hope is that this collaboration will unveil breakthrough science that we can apply to transformational drug discovery and development of novel immune therapies for melanoma patients in need."